Last updated on November 2018

Pembrolizumab in Combination With Doxorubicin in Advanced Recurrent or Metastatic Endometrial Cancer

Brief description of study

This is a non-randomized, single arm, multi-center, phase II study of pembrolizumab in combination with doxorubicin in subjects with recurrent/metastatic endometrial cancer.

Clinical Study Identifier: NCT03276013

Contact Investigators or Research Sites near you

Start Over

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.